ArticleScientific reports2026
Characteristics of the gut mycobiome in patients with membranous nephropathy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Membranous nephropathy (MN), the most common causes of nephrotic syndrome in adults, is known to be associated with a disordered gut microbiota. However, the relationship between the gut mycobiome and MN remains largely unclear. This study aimed to reveal the characteristics of gut mycobiome and explore the potential discrimination ability of intestinal fungi in patients with MN. We collected 154 fecal samples from the First Affiliated Hospital of Zhengzhou University. Internal transcribed spacer (ITS) sequencing was used to analyze the diversity and composition of gut mycobiome. Optimum operational taxonomic units (OTUs) were obtained for constructing a model to distinguish MN patients and controls. In addition, we analyzed whether gut mycobiome profiles correlated with clinical parameters of MN using Spearman correlation analyses. Fungal diversity was decreased in patients with MN. The relative abundance of fungal species also changed significantly. The optimal 6 OTUs markers were selected through a fivefold cross-validation on a random forest model and achieved an area under the curve of 0.986 (95% CI 0.9638-1) between 34 UMN and 34 HC samples. Our results reveal the diversity and composition of the gut mycobiome are significantly altered in MN patients. Gut mycobiome analysis may serve as a tool to discriminate MN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.